 PolarityTE Inc NASDAQ: PTE has announced preliminary topline data from a multi-center randomized controlled trial evaluating SkinTE for the treatment of Diabetic Foot Ulcers. The 100-subject trial, which assessed SkinTE plus standard of care SOC vs. 